Bone density and fracture risk reduction
Vitamin K2 MK-7 activates osteocalcin — the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Without adequate K2, supplemental calcium circulates unbound and deposits in arteries rather than bones. A 3-year double-blind RCT confirmed MK-7 (180 mcg/day) significantly improved bone mineral density and bone strength markers vs. placebo in postmenopausal women, with the longest placebo-controlled bone study published for a K2 supplement.
Cardiovascular protection — preventing arterial calcification
Matrix Gla protein (MGP) is the body's primary inhibitor of vascular calcification — but it requires Vitamin K2 to become activated (carboxylated). Inadequate K2 leaves MGP inactive, allowing calcium to deposit in arterial walls, increasing arterial stiffness and cardiovascular risk. Clinical studies confirm MK-7 supplementation significantly reduces circulating inactive-MGP (a marker of arterial calcification risk) and improves arterial stiffness in adults.
PMS symptom management
Clinical research on MK-7 demonstrates reduction in PMS-associated symptoms including mood changes, cramps, and bloating — attributed to K2's role in progesterone receptor activation and modulation of prostaglandin pathways that drive menstrual cramping. This positions K2Quest® for women's health formulations combining bone, cardiovascular, and hormonal benefits.
Carboxylation of Gla-proteins: osteocalcin and MGP activation
Vitamin K2 serves as the essential cofactor for gamma-glutamyl carboxylase — the enzyme that carboxylates (activates) Gla-domain proteins including osteocalcin and matrix Gla protein (MGP). Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and calcium ions, anchoring them in bone matrix for density and strength. Carboxylated MGP actively chelates calcium ions in vessel walls and inhibits vascular smooth muscle calcification. Without adequate K2, both proteins remain inactive (undercarboxylated), resulting in bone loss AND arterial calcification — explaining the strong epidemiological association between K2 intake and both bone and cardiovascular health.
Randomized, double-blind, placebo-controlled trial of MK-7 (180 mcg/day) in 244 healthy postmenopausal women over 3 years. Published in Osteoporosis International.
244 healthy postmenopausal women. 3-year RCT — longest placebo-controlled K2 bone study.
MK-7 significantly preserved bone mineral density at lumbar spine, femoral neck, and hip vs. placebo. Bone strength markers (stiffness index) improved. Undercarboxylated osteocalcin (inactive K2 marker) reduced. Well-tolerated across 3 years. Confirms long-term MK-7 supplementation for bone health.